Yue Huang received her Ph.D. from University of Washington. After joining AstraZeneca in 2016, she focused on supporting various projects with LCMS-based techniques. The LCMS bioanalytical techniques have been applied to support various project from preclinical to early clinical stage, ranging from therapeutic peptides to bio-conjugates such as ADCs, as well as small molecule excipients and monoclonal antibodies. Yue have extensive experience with method development of hybrid LC-MS/MS assays for the absolute quantification and comprehensive characterization of the in vivo biotransformations of structurally complex molecules. The results from her work informed key decision-making for several drug candidates.